The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases

Sponsor
China Medical University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05670262
Collaborator
(none)
6,000
1
53.9
111.3

Study Details

Study Description

Brief Summary

A birth cohort study to evaluate the role of human microbiome and vitamin D in the development of allergic diseases in young child before one year of age.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Allergic diseases are chronic inflammatory disorders that frequently affect young infants before one year of age, and is the beginning of allergy march in later life. The prevalence is increasing in industrial world, Taiwan included. Genetic and environmental factors, such exposure to allergens and microbes, especially early in life, have a detrimental role in the development of allergic diseases, such as atopic dermatitis (AD), allergic rhinitis and asthma. Vitamin D has an important role in different allergic disease. Lower cord blood vitamin D status was observed in infants that developed eczema. Vitamin D binding protein (DBP) bound to vitamin D and regulated its metabolites in the circulation. Moreover, vitamin D receptors have been identified on nearly all cells of the immune system. It may contribute to maintenance of intestinal barrier function by preventing increased intestinal permeability, dysbiosis, inflammation, and a lack of immune tolerance in the gut.

    Although aberrant interactions between gut microbes and the intestinal immune system have been implicated in this allergic disease, however, the causal effect of microbiota colonization of the gut and vitamin D that influence the development of allergic diseases, such as AD, in young infants is still unknown. The investigators plan to design a birth cohort study to evaluate the role of human microbiome and vitamin D in the development of allergic diseases in young child before one year of age.

    In this study, the investigators will recruit mother-infant pairs in antenatal clinics in China Medical University Hospital and China Medical University Children's Hospital. Newborns who have been enrolled at birth are collected for meconium samples before discharged from nursery and eligible for follow-up visits, and collect their nasal and anal swab microbiome samples at 2 and 12 months follow-up visit. Parental questionnaires are collected at 6, and 12 months of age. All infants were assessed at birth, 2 and 6, and 12 months of age. Assessment included physical examination for allergic diseases. In addition, infants at 12 months of age were collected their 3cc of blood sample.

    The investigators believe this longitudinal and prospective study, to follow-up infants from the date of birth until one years old, can answer the cause-effect relationships of microbiota and vitamin D in the development of allergic diseases, and design a microbiota-related preventive and treatment strategy.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    6000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases
    Actual Study Start Date :
    Aug 4, 2022
    Anticipated Primary Completion Date :
    Jan 31, 2027
    Anticipated Study Completion Date :
    Jan 31, 2027

    Outcome Measures

    Primary Outcome Measures

    1. Microbiome [Month 0]

      Meconium samples will be used to detect intestinal microbiome by using 16S rRNA sequencing to determine baseline status.

    2. Microbiome [Month 2]

      Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing to determine baseline status.

    3. Microbiome [Month 12]

      Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing,and to follow the change from baseline in microbiome at month 12.

    4. Levels of vitamin D [Month 12]

      Vitamin D will be measured in a blood sample by ELISA.

    5. Single nucleotide polymorphism of vitamin D receptor and vitamin D binding protein [Month 12]

      Single nucleotide polymorphism (SNP) genotyping will be performed in a blood sample by using TaqMan SNP genotyping assays.

    6. Total immunoglobulin E (IgE) [Month 12]

      Plasma total IgE concentration will be measured by microparticle immunoassay (IMx analyzer, Abbott Laboratories, Abbott Park, IL) and ELISA.

    7. Allergen-specific immunoglobulin E (IgE) [Month 12]

      Plasma allergen-specific IgE will be measured by BioIC ®.

    Secondary Outcome Measures

    1. Parental questionnaire (0-6 month) [Month 6]

      For assessing child's health, feeding habit, and environmental exposure

    2. Parental questionnaire (6-12 month) [Month 12]

      For assessing child's health, feeding habit, and environmental exposure

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    0 Years to 1 Year
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • All term newborn babies who are born in China Medical University Hospital. The term baby defines the maternal gestational age between 37 0/7 weeks to 41 6/7 weeks.
    Exclusion Criteria:
    • The exclusion criteria are prematurity newborn, congenital anomalies and cardiopulmonary failure need for resuscitation immediately after birth.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 China Medical University Hospital Taichung Taiwan 404

    Sponsors and Collaborators

    • China Medical University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    China Medical University Hospital
    ClinicalTrials.gov Identifier:
    NCT05670262
    Other Study ID Numbers:
    • CMUH111-REC2-033
    First Posted:
    Jan 4, 2023
    Last Update Posted:
    Jan 4, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by China Medical University Hospital

    Study Results

    No Results Posted as of Jan 4, 2023